--- title: Why underpowered studies are more dangerous than you think description: Underpowered studies distort effect estimates, reduce the reliability of published findings and introduce avoidable bias into the evidence base. image: https://blog.healthverity.com/hubfs/why-underpowered-studies-are-more-dangerous-than-you-think2.png --- Announcing HealthVerity Precision Event Alerts, a next-generation physician alerting solution. [Learn more](https://healthverity.com/news/healthverity-precision-event-alerts-launch/) - [Contact](https://healthverity.com/contact/) - [Sign In](https://marketplace.healthverity.com/login/?next=/marketplace/) [![HealthVerity-Logo-Dark-3](https://blog.healthverity.com/hs-fs/hubfs/HealthVerity-Logo-Dark-3.png?width=1662&height=320&name=HealthVerity-Logo-Dark-3.png)](https://healthverity.com/) - How We Help - Featured Content - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Life Sciences](https://healthverity.com/life-sciences/) - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - Data Ecosystem - [HealthVerity MarketplaceTM](https://healthverity.com/marketplace/healthverity-marketplace/) - [HealthVerity TaxonomySM](https://healthverity.com/taxonomy-portal/) - [Precision Event Alerts](https://healthverity.com/precision-event-alerts/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/portal/) - [Media Measurement](https://healthverity.com/media-measurement/) - [Insurance Underwriting](https://healthverity.com/insurance-underwriting/) - Technology Products - [Identity Manager (HVID)](https://healthverity.com/identity-manager/) - [HealthVerity FLOW](https://healthverity.com/flow/portal/) - [Governance Manager](https://healthverity.com/governance-manager/) - [Smart Contracts](https://healthverity.com/smart-contracts-manager/) - Symphony - Symphony Health Platform - [Symphony Health Overview](https://healthverity.com/symphony-health/overview/) - [Integrated Dataverse](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - Symphony Solutions - [Health technology and business intelligence solutions](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Integrated Dataverse and Source Solutions](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [Brand strategy and sales](https://healthverity.com/symphony-health/optimize-brand-strategy-and-sales-effectiveness/) - [HealthRankings](https://healthverity.com/symphony-health/health-rankings/) - [Market access](https://healthverity.com/symphony-health/solve-market-access-challenges/) - [Patient Journey](https://healthverity.com/symphony-health/understand-the-patient-journey/) - [Medicines affordability](https://healthverity.com/symphony-health/making-medicines-more-affordable/) - Symphony Products - [PayerSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PayerSource.pdf) - [PrescriberSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PrescriberSource.pdf) - [PatientSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSource.pdf) - [PatientSourceCompleteTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceComplete.pdf) - [PatientSourceDUOTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-PatientSourceDUO.pdf) - [Symphony FLEXTM](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Symphony-FLEX.pdf) - [CustomerSource®](https://healthverity.com/symphony-health/integrated-dataverse-and-source-solutions/) - [DiagnosticSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-DiagnosticSource.pdf) - [NonRetailSource®](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-NonRetailSource.pdf) - Symphony Technology - [Symphony HealthCloud](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Synoma Data Integration](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/) - [Vantage Applications](https://blog.healthverity.com/hubfs/HealthVerity-Symphony-PDFs/HealthVerity-Symphony-Health-Factsheet-Vantage-Applications.pdf) - [Metys](https://healthverity.com/symphony-health/health-technology-and-business-intelligence-solutions/metys/) - Who We Serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) - Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) - [Zombie Data Explained](https://healthverity.com/get-verified/) - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) [Contact](https://healthverity.com/contact/) [Sign In](https://marketplace.healthverity.com/) [![Logo](https://blog.healthverity.com/hubfs/social-suggested-images/healthverity.comwp-contentuploadshealthverity-2023-logo2x.png)](https://healthverity.com/) - How We Help - Symphony - Who We Serve - Resources - [Careers](https://healthverity.com/careers/) - [About Us](https://healthverity.com/about-us/) [Request Demo](https://healthverity.com/request-demo/) Featured Content ###### HealthVerity MarketplaceTM The nation’s largest healthcare and consumer data ecosystem ###### taXonomy Pathways Unique features per therapeutic area with claims, labs and EHR including notes ###### HealthVerity eXOs AI-native real-world evidence generation ###### Identity Manager (HVID) Standalone de-identification as a service Data Ecosystem HealthVerity MarketplaceTM HealthVerity TaxonomySM HealthVerity Notes Precision Event Alerts HealthVerity Mastersets Media Measurement Syndicated Audiences Insurance Underwriting Technology Products Identity Manager (HVID) HealthVerity for Clinical Trial Linkage HealthVerity for Commercial Smart Contracts HealthVerity for Registries Symphony Health Platform ###### Symphony Health Overview Seamless Data. Stronger Insights. Smarter Decisions. ###### Integrated Dataverse Integrated Dataverse (IDV®) is de-identified claims data platform that combines medical, hospital, prescription, and demographic data into a single unifed view. ###### Symphony HealthCloud Securely store, integrate, access, and analyze virtually unlimited volumes of data with Symphony HealthCloud. Symphony Solutions Health technology and business intelligence solutions Integrated Dataverse and Source Solutions Brand strategy and sales HealthRankings Market access Patient Journey Medicines affordability Symphony Products PayerSource® PrescriberSource® PatientSource® PatientSourceCompleteTM PatientSourceDUOTM Symphony FLEXTM CustomerSource® DiagnosticSource® NonRetailSource® Symphony Technology Symphony HealthCloud Synoma Data Integration Vantage Applications Metys ###### Life Sciences Technology solutions from development through commercialization ###### Channel Partners HealthVerity enables partners to unlock unprecedented value and insights for clients ###### Government Comprehensive and compliant solutions to manage the nation’s care ###### Data Ecosystem Partners Join the nation’s largest data partner ecosystem ###### Insurance Insurance-grade solutions that excel in managing risk and rebates ###### HealthVerity Blog Insights and updates from industry experts ###### Publications Peer-reviewed research and discoveries ###### News & Events Stay informed about our latest announcements and happenings ###### The IPGE Approach Fundamentals that power everything that we do and every solution we offer ###### Resource Library Explore guides, webinars, and tools to enhance your understanding ###### Zombie Data Explained Learn how data quality drives better research outcomes # Why underpowered studies are more dangerous than you think [By - HealthVerity,](https://blog.healthverity.com/author/healthverity) May 20, 2026 ![](https://blog.healthverity.com/hubfs/why-underpowered-studies-are-more-dangerous-than-you-think2.png) In epidemiology, statistical power determines whether a study can accurately detect an effect of a given size with a specified probability, typically 80% or higher. When studies fall below that threshold, the consequences extend well beyond inconclusive results. Underpowered studies distort effect estimates, reduce the reliability of published findings and introduce avoidable bias into the evidence base. For teams working in real-world data (RWD) and real-world evidence (RWE), this has direct implications for regulatory decisions, safety monitoring and commercial strategy. ## False negatives: failure to detect true effects Low statistical power increases the probability of a Type II error, where a study fails to reject a null hypothesis when a true, significant effect exists. In practice, this means: - True associations between exposures and outcomes are missed - Treatment effects appear null despite clinically meaningful benefits - Safety signals remain undetected - Meaningful disease predictors go unobserved This is not a neutral outcome and when evidence is interpreted as "no effect," underpowered studies can result in delayed intervention, misinform clinical guidance and bias downstream meta-analyses. ## Effect size inflation and the winner’s curse When underpowered studies produce statistically significant findings, the observed effect sizes are often overestimated. This pattern is commonly referred to as the winner’s curse. In small samples, only large observed effects tend to reach conventional significance thresholds, such as p < 0.05. These estimates are more likely to reflect random variation or noise rather than the true underlying effect. As a result, reported effect sizes may be systematically overestimated, while subsequent, well-powered studies often produce attenuated estimates. Over time, this can create apparent inconsistencies across the literature, contributing to replication failure and weakening confidence in early evidence.   ## Low positive predictive value and false discoveries Statistical significance does not guarantee that a finding is true. In low-power settings, the positive predictive value (PPV) of a significant result declines. PPV depends on statistical power, the Type I error rate and the prior probability of a true effect. When power is low, even a nominal alpha of 0.05 yields a higher proportion of false positives among significant findings. Contributing factors include: - Random error amplified by small sample size - Residual confounding - Model instability and overfitting The result is a body of literature with a higher signal-to-noise ratio, where spurious associations are more likely to be published and pursued. ## Ethical implications in human research Clinical and population health studies rely on participant contribution under an implicit expectation that the research will generate scientific value. Underpowered designs raise ethical concerns when participants are exposed to risk without a reasonable probability of producing informative results. They also limit the study’s ability to answer the research question it poses and divert resources from studies with stronger design rigor. For this reason, institutional review boards and funding bodies increasingly evaluate statistical power as a core component of ethical study design.   ## Resource inefficiency and cumulative bias Underpowered studies consume time, funding and data infrastructure while contributing limited reliable evidence. More importantly, they introduce bias into the cumulative evidence base: - Meta-analyses may incorporate inflated or null-biased estimates - Research agendas shift toward non-reproducible findings - Decision-making relies on unstable evidence In aggregate, this slows scientific progress and increases the cost of generating reliable real-world evidence. ## Why this matters for real-world data research Real-world data studies often involve complex cohorts, heterogeneous populations and observational designs that are already susceptible to bias. Insufficient power compounds these challenges by making it harder to distinguish meaningful effects from random variation. These issues become especially visible when cohort definitions are overly restrictive, rare outcomes are evaluated without adequate follow-up or subgroup analyses are conducted without sufficient events per variable. In each case, the study may appear analytically sound while lacking the statistical foundation needed to produce stable, interpretable results. Designing real-world data studies with adequate power requires careful alignment between the research question, appropriate patient controls, outcome incidence and available data. Researchers need to understand whether the dataset can support the intended analysis before results are generated. This includes pressure-testing cohort definitions, expected event counts and follow-up windows against the realities of the available data. That planning helps ensure the study can produce evidence that is fit for decision-making.   ## The bottom line Underpowered studies introduce systematic error into effect estimation and interpretation, raising the risk of misleading conclusions. For epidemiology and RWE teams, sufficient statistical power is essential for valid inference, reproducibility and ethical research that supports reliable scientific and clinical decision-making.   [![Explore real-world data in HealthVerity Marketplace ](https://no-cache.hubspot.com/cta/default/5412465/interactive-192965525172.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLL5i5lxOahXnM3LV9DPRj4CLKXh52GgBrxX2Vsk%2Ba%2FCaTZTqOCwYencFBMwnFZm4Cxm46vwXqpxJrMePLiqNV4IU0t6ToS%2BrQUWrPVevU9d3jzTYPyiivExYkdpF802fCXcJfKjMzY5JLzdur7PF3AeHgoa6tXk8e7kQsNNvFuevHCeveaoKBhfa57BBKmt%2FaT5TUhNhoGRnMr97N7VK4uU&webInteractiveContentId=192965525172&portalId=5412465) [![Explore RWD in HealthVerity Marketplace™](https://no-cache.hubspot.com/cta/default/5412465/interactive-195733501532.png)](https://blog.healthverity.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKOKrXdeCXbs%2BKjkX3dwdoA29xZAaOOoySJLMvSRycQPI%2FYzxi80%2Bw9w8BK1BMUg0G1Y7O2UXOujdklxb95fcKkYfXcg4pTW1qYrJB1%2Bypw03fFtLbt85RdHxV8tEUKnGxzhcUGH1QKl9Oo%2FUBx%2B2rmaESganeFQBPxvpIMpKO5f4zo1aCgBfo%3D&webInteractiveContentId=195733501532&portalId=5412465) ###### Category - [Solutions & Best Practices](https://blog.healthverity.com/tag/solutions-best-practices) - [Trends & Insights](https://blog.healthverity.com/tag/trends-insights) - [HEOR](https://blog.healthverity.com/tag/heor) - [Marketplace](https://blog.healthverity.com/tag/marketplace) - [Thought Leadership](https://blog.healthverity.com/tag/thought-leadership) - [taXonomy](https://blog.healthverity.com/tag/taxonomy) - [Industry Updates](https://blog.healthverity.com/tag/industry-updates) - [Case Studies](https://blog.healthverity.com/tag/case-studies) - [Government](https://blog.healthverity.com/tag/government) - [Commercial Pharmaceutical](https://blog.healthverity.com/tag/commercial-pharmaceutical) - [AI](https://blog.healthverity.com/tag/ai) - [eXOs](https://blog.healthverity.com/tag/exos) - [Audiences](https://blog.healthverity.com/tag/audiences) - [taXonomy Pathways](https://blog.healthverity.com/tag/taxonomy-pathways) - [Notes](https://blog.healthverity.com/tag/notes) - [Rare Diseases](https://blog.healthverity.com/tag/rare-diseases) ###### Popular Post - [The GLP-1 trend: What the real-world data reveals](https://blog.healthverity.com/the-glp-1-surge-what-the-real-world-data-reveals) - [GLP-1 trends 2025: real-world data, patient outcomes & future therapies](https://blog.healthverity.com/glp-1-trends-2025-real-world-data-patient-outcomes-future-therapies) - [Open claims vs. closed payer claims: What’s the difference?](https://blog.healthverity.com/open-claims-vs-closed-payer-claims) - [GLP‑1 real‑world data for obesity: A new standard for metabolic care](https://blog.healthverity.com/glp-1-real-world-data-for-obesity-a-new-standard-for-metabolic-care) - [What is Privacy Preserving Record Linkage (PPRL)?](https://blog.healthverity.com/what-is-privacy-preserving-record-linkage) ###### Subscribe ### Similar Blogs [![More than data: Synchronizing the breast cancer patient story](https://blog.healthverity.com/hs-fs/hubfs/more-than-data-synchronizing-the-breast-cancer-patient-story.jpg?width=352&name=more-than-data-synchronizing-the-breast-cancer-patient-story.jpg)](https://blog.healthverity.com/breast-cancer-patient-story) #### [More than data: Synchronizing the breast cancer patient story](https://blog.healthverity.com/breast-cancer-patient-story) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 25 October 2023 One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime, that’s one... [READ MORE](https://blog.healthverity.com/why-underpowered-studies-are-more-dangerous-than-you-think) [![How taXonomy Pathways builds comprehensive patient journeys](https://blog.healthverity.com/hs-fs/hubfs/pathways-blog-featured.png?width=352&name=pathways-blog-featured.png)](https://blog.healthverity.com/how-taxonomy-pathways-builds-comprehensive-patient-journeys) #### [How taXonomy Pathways builds comprehensive patient journeys](https://blog.healthverity.com/how-taxonomy-pathways-builds-comprehensive-patient-journeys) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 21 October 2025 In a recent webinar, the HealthVerity team including Alexa Woodward, Ph.D., Director of Strategic... [READ MORE](https://blog.healthverity.com/why-underpowered-studies-are-more-dangerous-than-you-think) [![Insights from IMPACCT 2025: advancing real-world evidence](https://blog.healthverity.com/hs-fs/hubfs/impact-rwe-2025-featured.png?width=352&name=impact-rwe-2025-featured.png)](https://blog.healthverity.com/insights-from-impacct-2025-advancing-real-world-evidence) #### [Insights from IMPACCT 2025: advancing real-world evidence](https://blog.healthverity.com/insights-from-impacct-2025-advancing-real-world-evidence) By [HealthVerity](https://blog.healthverity.com/author/healthverity) 4 November 2025 Identifying the gaps in today’s real-world data The 2025 IMPACCT Real-World Evidence Summit brought... [READ MORE](https://blog.healthverity.com/why-underpowered-studies-are-more-dangerous-than-you-think) #### Who we serve - [Life Sciences](https://healthverity.com/life-sciences/) - [Government](https://healthverity.com/government/) - [Insurance](https://healthverity.com/insurance/) - [Channel Partners](https://healthverity.com/channel-partners/) - [Data Ecosystem Partners](https://healthverity.com/data-ecosystem-partners/) #### How we help - [HealthVerity Marketplace](https://healthverity.com/marketplace/) - [HealthVerity Mastersets](https://healthverity.com/mastersets/) - [HealthVerity FLOW](https://healthverity.com/flow/) - [The IPGE Approach](https://healthverity.com/ipge-approach/) #### Resources - [HealthVerity Blog](https://blog.healthverity.com/) - [News & Events](https://healthverity.com/resources/news-and-events/) - [Resource Library](https://healthverity.com/resources/resource-library/) - [Publications](https://healthverity.com/resources/publications/) #### Our company - [About Us](https://healthverity.com/about-us/) - [Leadership](https://healthverity.com/about-us/#leadership) - [Board of Directors](https://healthverity.com/about-us/#board) - [Careers](https://healthverity.com/careers/) - [Contact](https://healthverity.com/contact/) ©2026 HealthVerity, Inc.    |    [Terms & Conditions](https://healthverity.com/terms-and-conditions/)    |    [Privacy Policy](https://healthverity.com/privacy-policy/) ![](https://px.ads.linkedin.com/collect/?pid=4361946&fmt=gif) ```json { "@context" : "https://schema.org", "@type" : "BlogPosting", "author" : { "@type" : "Organization", "name" : "HealthVerity" }, "datePublished" : "2026-08-31", "description" : "Discover the hidden risks of underpowered clinical studies. Learn how insufficient sample sizes lead to false negatives, wasted resources, and how real-world data (RWD) can help ensure statistical power.", "headline" : "Why underpowered studies are more dangerous than you think", "keywords" : [ "underpowered studies", "statistical power in research", "Type II error", "clinical trial sample size", "false negatives in research", "real-world data for clinical trials", "RWE study design", "HEOR analytics" ], "mainEntityOfPage" : { "@id" : "https://blog.healthverity.com/why-underpowered-studies-are-more-dangerous-than-you-think", "@type" : "WebPage" }, "publisher" : { "@type" : "Organization", "logo" : { "@type" : "ImageObject", "url" : "https://healthverity.com/wp-content/uploads/2023/08/healthverity-logo.png" }, "name" : "HealthVerity" } } ``` ```json { "@context" : "https://schema.org", "@type" : "FAQPage", "mainEntity" : [ { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "An underpowered study is a research study that lacks a sufficient sample size to reliably detect a true effect or difference between groups, if one actually exists. In biostatistics, these studies are generally considered to have a statistical power of less than 80%." }, "name" : "What is an underpowered study?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Underpowered studies are dangerous because they frequently result in false negatives (Type II errors), concluding a drug or intervention does not work when it actually does. This can lead to the abandonment of life-saving therapies, misinformed clinical guidelines, and wasted research funding." }, "name" : "Why are underpowered studies considered dangerous in healthcare?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "A Type II error (false negative) occurs when a study fails to reject a false null hypothesis. In clinical research, this means the study concludes that a treatment has no effect, even though the treatment is genuinely effective. Underpowered studies are the primary cause of Type II errors." }, "name" : "What is a Type II error in clinical research?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Low statistical power drastically reduces reproducibility. If an underpowered study happens to find a statistically significant result, it is often an exaggeration of the true effect (the 'winner's curse'). Consequently, when other researchers attempt to replicate the study with proper sample sizes, the findings do not hold up." }, "name" : "How does statistical power affect the reproducibility of a study?" }, { "@type" : "Question", "acceptedAnswer" : { "@type" : "Answer", "text" : "Real-world data allows researchers to accurately forecast cohort availability before a study begins. By utilizing massive, interconnected datasets like the HealthVerity Marketplace, researchers can verify that they have access to a large enough patient population to achieve the statistical power necessary for conclusive results." }, "name" : "How can real-world data (RWD) help prevent underpowered studies?" } ] } ``` ```json { "@context" : "https://schema.org", "@type" : "BreadcrumbList", "itemListElement" : [ { "@type" : "ListItem", "item" : "https://healthverity.com/", "name" : "Home", "position" : 1 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/", "name" : "Blog", "position" : 2 }, { "@type" : "ListItem", "item" : "https://blog.healthverity.com/why-underpowered-studies-are-more-dangerous-than-you-think", "name" : "Why underpowered studies are more dangerous than you think", "position" : 3 } ] } ```